A comparative study into the mechanisms of action of anti-tumor necrosis factor α, anti-CD4, and combined anti-tumor necrosis factor α/anti-CD4 treatment in early collagen-induced arthritis

Arthritis and Rheumatism

Volumn 43, Issue 3, 2000, Pages 638-644

  Marinova Mutafchieva, Lilia ^a   Williams, Richard O ^a   Mauri, Claudia ^a   Mason, Lesley J ^a   Walmsley, Marita J ^a   Taylor, Peter C ^a   Feldmann, Marc ^a   Maini, Ravinder N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 4; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES; ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; COLLAGEN; DRUG THERAPY, COMBINATION; IMMUNOHISTOCHEMISTRY; INGUINAL CANAL; INTEGRIN ALPHA4BETA1; INTEGRINS; INTERFERON TYPE II; JOINTS; LYMPH NODES; MALE; MICE; MICE, INBRED DBA; RECEPTORS, LYMPHOCYTE HOMING; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0034039973     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200003)43:3<638::AID-ANR21>3.0.CO;2-R     Document Type: Article

References (42)

1. Moreland LW, Heck LW Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997;40:397-409.
2. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smollen JS, et al. Treatment with a chimaeric monoclonal antibody to tumour necrosis factor a suppresses disease activity in rheumatoid arthritis: results of a multi-centre, randomised, double blind trial. Lancet 1994;344:1105-10.
3. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
4. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
5. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
6. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor a antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
7. Stuart JM, Townes AS, Kang AH. Collagen autoimmune arthritis. Annu Rev Immunol 1984;2:199-218.
8. Ranges GE, Sriram S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985;162:1105-10.
9. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
10. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91: 2762-6.
11. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995; 84:433-9.
12. Sheehan KC, Ruddle NH, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 1989;142:3884-93.
13. Galfre G, Milstein C, Wright B. Rat X rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature 1979;277: 131-3.
14. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984;312:548-51.
15. Qin S, Cobbold S, Tighe H, Benjamin R, Waldmann H. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 1987;17:1159-65.
16. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997;107:507-12.
17. Miyake K, Weissman IL, Greenberger JS, Kincade PW. Evidence for the role of the integrin VLA-4 in lymphohemopoiesis. J Exp Med 1991;173:599-607.
18. Miyake K, Medina K, Ishihara K, Kimoto M, Auerbach R, Kincade PW. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J Cell Biol 1991;14:557-65.
19. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996;26:1511-8.
20. Wilkinson LS, Edwards JCW, Poston RN, Haskard OD. Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. Lab Invest 1993;68:82-9.
21. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
22. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor a and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992;89:7375-9.
23. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510-4.
24. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
25. Issekutz AC, Meager A, Otterness I, Issekutz TB. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 1994;97:26-32.
26. Lewthwaite J, Blake S, Hardingham T, Foulkes R, Stephens S, Chaplin L, et al. Role of TNFα in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralising monoclonal antibodies. Ann Rheum Dis 1995; 54:366-74.
27. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumour necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350.
28. Mauri C, Chu CQ, Woodrow D, Mori L, Londei M, Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. J Immunol 1997; 159:5032-41.
29. Choy EHS, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992;36:291-8.
30. Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJM, Kluin PM, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
31. Choy EHS, Pitzalis C, Cauli A, Bijl JA, Schantz A, Woody J, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement: implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996;39:52-6.
32. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990;33:768-73.
33. Noble PW, McKee CM, Cowman M, Shin HS. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 1996;183:2373-8.
34. Durie FH, Fava RA, Noelle RJ. Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 1994;73:11-8.
35. Goldschmidt TJ, Andersson M, Malmstrom V, Holmdahl R. Activated type II collagen reactive T cells are not eliminated by in vivo anti-CD4 treatment: implications for therapeutic approaches on autoimmune arthritis. Immunobiology 1992;184:359-71.
36. + cells in patients with rheumatoid arthritis. J Autoimmun 1997;10:87-97.
37. Rep MH, van Oosten BW, Roos MT, Ader HJ, Polman CH, van Lier RA. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting Th1 cells in humans. J Clin Invest 1997;99:2225-31.
38. Perosa F, Scudeletti M, Imro MA, Dammacco F, Luccarelli G, Indiveri F. Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases. Clin Exp Rheumatol 1997;15:201-10.
39. Williams RO, Mauri C, Mason LJ, Marinova-Mutafchieva L, Ross SE, Feldmann M, et al. Therapeutic actions of cyclosporine and anti-tumor necrosis factor a in collagen-induced arthritis and the effect of combination therapy. Arthritis Rheum 1998;41:1806-12.
40. Van den Berg WB, Joosten LA, Helsen M, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994;95:237-43.
41. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
42. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42:498-506.